Cyclo Therapeutics Receives Positive EMA Pediatric Committee Opinion For Trappsol CycloBenzinga • 03/09/21
Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™Business Wire • 03/09/21
Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type CBusiness Wire • 03/04/21
Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical OfficerBusiness Wire • 03/01/21
Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and FamiliesBusiness Wire • 02/22/21
Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021Business Wire • 02/09/21
Cyclo Therapeutics to Present on Its Clinical and Drug Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021Business Wire • 01/26/21